8-K: Rigel Pharmaceuticals Announces 1-for-10 Reverse Stock Split to Boost Share Price and Maintain Nasdaq Listing

Rigel Pharmaceuticals will implement a 1-for-10 reverse stock split effective June 27, 2024, to increase its share price and maintain Nasdaq compliance.

Summary

• Rigel Pharmaceuticals has announced a 1-for-10 reverse stock split of its common stock.
• The reverse stock split will be effective on June 27, 2024, at 12:01 a.m. Eastern Time.
• Trading on a split-adjusted basis will begin at market open on June 27, 2024.
• Every 10 shares of pre-split common stock will be converted into one new share.
• The number of outstanding shares will decrease from approximately 175,582,945 to approximately 17,558,294.
• Fractional shares will not be issued; instead, shareholders will receive cash payments.
• The primary goal of the reverse stock split is to increase the per-share trading price.
• This action aims to improve the company's marketability to institutional investors and maintain Nasdaq listing compliance.

Sentiment

Score: 5

Explanation: The document is neutral, detailing a reverse stock split which is a common corporate action. While it aims to improve the company's position, it also highlights underlying issues with the share price.

Positives

• The reverse stock split is intended to increase the per-share trading price of Rigel's common stock.
• The company believes this will improve marketability to institutional investors.
• The action is expected to help maintain compliance with Nasdaq's minimum bid price requirement for continued listing.
• Registered stockholders holding shares electronically do not need to take any action.

Negatives

• The reverse stock split reduces the number of outstanding shares, which could be perceived negatively by some investors.
• The company's low share price was cited as a reason for the reverse split, which may indicate underlying concerns about the company's performance.

Risks

• The company acknowledges risks associated with maintaining compliance with Nasdaq's continued listing requirements.
• The reverse stock split may not achieve the desired increase in share price or marketability.
• The company's future performance is subject to various risks and uncertainties.

Future Outlook

The company expects the reverse stock split to increase its per-share trading price, improve marketability to institutional investors, and help maintain compliance with Nasdaq listing requirements. However, the company acknowledges that these are forward-looking statements subject to risks and uncertainties.

Management Comments

• The primary objective in effectuating the Reverse Stock Split will be to attempt to raise the per-share trading price of the company's common stock.
• Rigel believes that the low per-share market price of its common stock impairs the company's marketability to, and acceptance by, institutional investors and other members of the investing public and creates a negative impression of the company.

Industry Context

Reverse stock splits are a common strategy for companies facing low share prices, often to avoid delisting from major exchanges like Nasdaq. This action is not unique to Rigel and is often seen in the biotechnology sector where companies may experience volatility in their stock price.

Comparison to Industry Standards

• Many biotechnology companies with low share prices have implemented reverse stock splits to maintain listing compliance, such as Agenus Inc. (AGEN) which recently completed a 1-for-10 reverse stock split.
• Similar to Rigel, companies like Cassava Sciences (SAVA) have used reverse stock splits to increase their share price and attract institutional investors.
• The 1-for-10 ratio is a common choice for reverse stock splits, aligning with industry practices to achieve a significant increase in share price while minimizing the impact on the number of outstanding shares.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant.
• Institutional investors may view the company more favorably due to the increased share price.
• The company aims to maintain its listing on the Nasdaq, which is important for investor confidence.

Next Steps

• The reverse stock split will be effective on June 27, 2024.
• Shares will begin trading on a split-adjusted basis on June 27, 2024.
• Stockholders holding shares in certificate form will receive a transmittal letter from Equiniti with instructions.

Key Dates

Keywords

reverse stock split, stock split, Nasdaq, RIGL, share price, listing compliance, institutional investors, marketability, biotechnology, equity